Search

Search Results

• P083 | EFFECT OF ATOGEPANT ON COGNITIVE FUNCTION FOLLOWING ACUTE TREATMENT OF MIGRAINE ACROSS MULTIPLE ATTACKS: RESULTS FROM THE ECLIPSE TRIAL

  R. Masselli¹, A. Van Dycke­­², G. Ahmadyar³, E. Brand-Schieber³, C. Castro³, R. Ornello⁴, L. Luo³, P. Pozo-Rosich^5|6, U. Reuter^7|8, K. Carr³, R. Gil-Gouveia^9|10 | ¹AbbVie Srl, Rome, Italy; ²Department of Neurology, General Hospital Sint-Jan Bruges, Belgium; ³AbbVie Inc. North Chicago, IL, USA; ⁴Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy; ⁵Headache Unit, Neurology Department, Vall d'Hebron University Hospital, Barcelona, Spain; Headache and Neurological Pain Research; ⁶Headache and Neurological Pain Research Group, Vall d'Hebron Institute of Research, Universitat Autonoma de Barcelona, Spain; ⁷University Hospital Bonn, Germany; ⁸Charité Universitätsmedizin Berlin, Germany; ⁹Neurology Department, Hospital da Luz, Lisboa, Portugal; ¹⁰Center for Interdisciplinary Research in Health, Universidade Católica Portuguesa, Lisboa, Portugal

  03-11-2026

  DOI https://doi.org/10.4081/cc.2026.16039

  • 0 abstract views
  • 0 PDF

• P078 | THE PATIENT JOURNEY OF RESISTANT AND REFRACTORY MIGRAINE: RESULTS FROM THE REFINE STUDY

  I. Gragnaniello¹, S. Sacco¹, A. Onofri¹, C. Rosignoli¹, V. Caponnetto¹, D. Bayar², M. Braschinsky³, M. Carnovali⁴, M. Gentile⁵, R. Gil-Gouveia⁶, G. Iaccarino⁷, C. Lampl⁸, A. Leheste³, P. Martelletti⁹, C. Mazzanti⁹, D. Mitsikostas¹⁰, A. Muñoz-Vendrell¹¹, R. Oliveira⁶, A. Ozge², I. Pavão Martins¹², P. Pozo-Rosich¹¹, M. Prudenzano⁵, K. Ryliskiene¹³, M. Sanchez del Rio¹⁴, J. Vainauskienė¹³, F. Vernieri⁷, M. Waliszewska-Prosół, Z. Katsarava⁴, A. Sinclair¹⁶, R. Ornello¹ | ¹University of L'Aquila, Department of Applied Clinical Sciences and Biotechnology, Italy; ²Mersin University Faculty of Medicine, Department of Neurology, Turkey; ³Headache Clinic, Tartu, Estonia; ⁴Evangelical Hospital, Unna, Germany; ⁵Centro Cefalee - Clinica Neurologica "L. Amaducci", Azienda Ospedaliero-Universitaria Policlinico Consorziale di Bari, Italy; ⁶Hospital da Luz - Center for Interdisciplinary Research in Health, Universidade Católica Portuguesa, Lisbon, Portugal; ⁷Cefalee e Neurosonologia-Policlinico Universitario Campus Bio-medico, Rome, Italy; ⁸Department of Neurology and Headache Medical Centre, Konventhospital Barmherzige Brüder Linz, Austria; ⁹University Sapienza, Rome, Italy; ¹⁰First Neurology Department, Aeginition Hospital, Medical School, National and Kapodistrian University of Athens, Greece; ¹¹Headache Unit and Research Group Vall d'Hebron University Hospital and Institute of Research, Universitat Autonoma de Barcelona, Spain; ¹²Faculdade de Medicine and Hospital Universitário de Santa Maria, Centro Hospitalar; Hospital Cuf Tejo, Lisbon, Portugal; ¹³Vilnius University Centre of Neurology, Kardiolitos klinikos Centre of Neurology, Lithuania; ¹⁴Clinica Universidad de Navarra, Madrid, Spain; ¹⁵Department of Neurology, Wroclaw Medical University, Poland; ¹⁶Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, United Kingdom

  03-11-2026

  DOI https://doi.org/10.4081/cc.2026.16034

  • 0 abstract views
  • 0 PDF

• OC07 | LONG-TERM COMBINATION WITH ONABOTULINUMTOXINA AND ATOGEPANT TO ACHIEVE HIGHER STANDARDS OF MIGRAINE CONTROL: A 52-WEEK, PROSPECTIVE, REAL-WORLD EVALUATION (SYNERGY STUDY)

  L. Francesco Iannone¹, M. Romozzi^2|3, A. Russo⁴, I. Finkelstein⁵, D. Seabi⁶, A. Ahlden⁶, A. Hege Aamodt^7|8|9, P. Calabresi^2|3, C. Vollono³, E. Caronna^10|11, P. Pozo-Rosich^10|11, E. Andreas Tronvik^8|12|13, C. Sundal^6|12 | ¹Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Italy; ²Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy; ³Neurologia, Dipartimento di neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; ⁴Inter-departmental Program of Headache Medicine and Primary Pain Syndromes, Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania “Luigi Vanvitelli”, Naples, Italy; ⁵Toronto Headache and Pain clinic; Pain Clinic, Toronto, Canada; ⁶NeuroClinicNorway, Lillestrøm, Norway; ⁷Department of Neurology, Oslo University Hospital, Rikshospitalet, Norway; ⁸NorHead, Norwegian Headache Research Centre; NTNU, Norwegian University of Science and Technology, Trondheim, Norway; ⁹Institute of Population Health, Faculty of Health and Life Sciences, University of Liverpool, UK; ¹⁰Headache and Neurological Pain Research Group, Vall d’Hebron Research Institute, Department of Neuroscience, Universitat Autònoma de Barcelona, Spain; ¹¹Headache Clinic, Neurology Department, Vall d’Hebron Hospital, Barcelona, Spain; ¹²Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway; ¹³Neuroclinic, St. Olavs Hospital, Trondheim, Norway

  03-11-2026

  DOI https://doi.org/10.4081/cc.2026.15945

  • 0 abstract views
  • 0 PDF